Cannabidiol, Morphine, Pain

Description

The purpose of the proposed study is to investigate the interaction of cannabidiol (CBD) and morphine effects on pain sensitivity. Cannabidiol is a cannabinoid (similar to cannabis, or marijuana) present in marijuana that alters some of the effects of marijuana.

Conditions

CBD, Chronic Pain

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the proposed study is to investigate the interaction of cannabidiol (CBD) and morphine effects on pain sensitivity. Cannabidiol is a cannabinoid (similar to cannabis, or marijuana) present in marijuana that alters some of the effects of marijuana.

Human Laboratory Model to Screen Drugs With Opioid Analgesic-sparing Effects: Cannabidiol/Morphine Combinations

Cannabidiol, Morphine, Pain

Condition
CBD
Intervention / Treatment

-

Contacts and Locations

Detroit

Tolan Park Medical Building, Detroit, Michigan, United States, 48201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants must report having smoked a cigarette (nicotine or marijuana) AND having taken an opioid on 3 or more occasions in their lifetime.
  • * Participants must be in good health to participate; those with certain contraindications will be excluded.
  • * All participants will undergo psychiatric evaluation and will be asked to report their substance use history by interview and structured questionnaire methods.
  • * Participants will undergo medical evaluations using medical history, physical exam, standard lab tests (complete blood chemistry, urinalysis, urine pregnancy test for females), and 12-lead ECG.
  • * Serious psychiatric illness (e.g. psychotic or bipolar disorder, recent suicide attempts; severe depression)
  • * Substance Use Disorders other than Nicotine Use Disorder and Mild Cannabis Use Disorder
  • * Neurological diseases; cardiovascular problems (e.g. systolic BP \>140 or \<95 mmHg, diastolic BP \>90 mmHg, abnormal ECG); pulmonary diseases; systemic diseases (e.g. liver, renal, inflammatory)
  • * Cognitive impairment (\<80 IQ)
  • * Past-month medications that increase study risk
  • * Women who are pregnant (urine HCG), lactating (self-report), or if heterosexually active and not using (self-report) medically approved birth control (oral or depot contraception, IUD, condom/foam, sterilization, tubal ligation)
  • * Individuals unable to give informed consent will be excluded.

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Wayne State University,

Leslie Lundahl, PhD, PRINCIPAL_INVESTIGATOR, Wayne State University

Study Record Dates

2025-01-26